0001104659-24-080214.txt : 20240716 0001104659-24-080214.hdr.sgml : 20240716 20240716163034 ACCESSION NUMBER: 0001104659-24-080214 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240712 FILED AS OF DATE: 20240716 DATE AS OF CHANGE: 20240716 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Shulman Joseph CENTRAL INDEX KEY: 0001909855 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38223 FILM NUMBER: 241119978 MAIL ADDRESS: STREET 1: C/O RHYTHM PHARMACEUTICALS STREET 2: 222 BERKELEY STREET, SUITE 1200 CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RHYTHM PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001649904 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 462159271 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 222 BERKELEY STREET STREET 2: 12TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 857-264-4280 MAIL ADDRESS: STREET 1: 222 BERKELEY STREET STREET 2: 12TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: RHYTHM METABOLIC, INC. DATE OF NAME CHANGE: 20150803 4 1 tm2419477-1_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-07-12 0 0001649904 RHYTHM PHARMACEUTICALS, INC. RYTM 0001909855 Shulman Joseph 222 BERKELEY STREET, 12TH FLOOR BOSTON MA 02116 0 1 0 0 Chief Technical Officer 1 Common Stock 2024-07-12 4 M 0 5313 21.38 A 5343 D Common Stock 2024-07-12 4 S 0 5313 50.0141 D 30 D Stock Option (right to buy) 21.38 2024-07-12 4 M 0 5313 0 D 2030-07-26 Common Stock 5313 1297 D The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted on May 5, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $50.00 to $50.07. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The stock options were granted on July 27, 2020. 25% of the shares subject to the option vested and became exercisable on July 27, 2021 and the remaining 75% of the shares subject to the option shall vest and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter. /s/ Christopher Paul German as Attorney-in-Fact for Joseph Shulman 2024-07-16